BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013;31:4325-32. [PMID: 24145347 DOI: 10.1200/JCO.2012.48.4923] [Cited by in Crossref: 141] [Cited by in F6Publishing: 77] [Article Influence: 17.6] [Reference Citation Analysis]
Number Citing Articles
1 Gao M, Yang G, Kong Y, Wu X, Shi J. Smoldering multiple myeloma. Biomed Res Int 2015;2015:623254. [PMID: 26000300 DOI: 10.1155/2015/623254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 2017;129:3452-64. [PMID: 28515094 DOI: 10.1182/blood-2017-03-773341] [Cited by in Crossref: 96] [Cited by in F6Publishing: 82] [Article Influence: 24.0] [Reference Citation Analysis]
3 Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:2159-64. [PMID: 27638366 DOI: 10.1016/j.bbmt.2016.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
4 Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv 2018;2:3149-54. [PMID: 30463914 DOI: 10.1182/bloodadvances.2018024794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
5 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020;10:94. [PMID: 32989217 DOI: 10.1038/s41408-020-00359-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 28.0] [Reference Citation Analysis]
6 Seckinger A, Hose D. [Interaction between myeloma cells and bone tissue]. Radiologe 2014;54:545-50. [PMID: 24832128 DOI: 10.1007/s00117-013-2626-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget 2014;5:10237-50. [PMID: 25296978 DOI: 10.18632/oncotarget.2529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
8 Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C, Neri A. Long Non-Coding RNAs in Multiple Myeloma. Genes (Basel) 2018;9:E69. [PMID: 29389884 DOI: 10.3390/genes9020069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
9 Bolomsky A, Hose D, Schreder M, Seckinger A, Lipp S, Klein B, Heintel D, Ludwig H, Zojer N. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol 2015;8:10. [PMID: 25887188 DOI: 10.1186/s13045-014-0105-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
10 Hamdaoui H, Benlarroubia O, Ait Boujmia OK, Mossafa H, Ouldim K, Belkhayat A, Smyej I, Benrahma H, Dehbi H, Chegdani F. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med 2020;8:e1363. [PMID: 32573970 DOI: 10.1002/mgg3.1363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100. [PMID: 26565896 DOI: 10.1002/ajh.24236] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
12 Errico A. Haematological cancer: abnormal chromosomes forecast rapid disease progression in SMM. Nat Rev Clin Oncol 2013;10:671. [PMID: 24217203 DOI: 10.1038/nrclinonc.2013.214] [Reference Citation Analysis]
13 Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. What Is New in the Treatment of Smoldering Multiple Myeloma? J Clin Med 2021;10:421. [PMID: 33499196 DOI: 10.3390/jcm10030421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2018;2:1470-9. [PMID: 29945937 DOI: 10.1182/bloodadvances.2018016998] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
15 Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel) 2021;13:3189. [PMID: 34202390 DOI: 10.3390/cancers13133189] [Reference Citation Analysis]
16 Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016;21:333-42. [PMID: 26921288 DOI: 10.1634/theoncologist.2015-0303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
17 Zhao AL, Shen KN, Wang JN, Huo LQ, Li J, Cao XX. Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies. Cancer Manag Res 2019;11:5599-611. [PMID: 31296995 DOI: 10.2147/CMAR.S205623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood 2014;124:3380-8. [PMID: 25298034 DOI: 10.1182/blood-2014-08-551549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
19 Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz M, Manasanch EE, Kazandjian D, Lesokhin A, Dogan A, Zhang Y, Mikulasova A, Walker B, Morgan G, Campbell PJ, Landgren O, Rummens JL, Bolli N, Maura F. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021;12:1861. [PMID: 33767199 DOI: 10.1038/s41467-021-22140-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
20 Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ 3rd, Benson JT, Kumar S, Rajkumar SV. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 2014;1:e28-36. [PMID: 25530988 DOI: 10.1016/S2352-3026(14)70001-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kim EB, Yee AJ, Raje N. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers (Basel) 2020;12:E1223. [PMID: 32414145 DOI: 10.3390/cancers12051223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Blum A, Bazou D, O'Gorman P. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood Lymphat Cancer 2018;8:21-31. [PMID: 31360091 DOI: 10.2147/BLCTT.S136447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
23 Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol 2020;6:425-32. [PMID: 31830214 DOI: 10.1001/jamaoncol.2019.4659] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
24 Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol 2019;187:588-94. [PMID: 31298751 DOI: 10.1111/bjh.16096] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
25 Tessier C, Allard T, Boudreault JS, Kaedbey R, Éthier V, Fortin F, Pavic M. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Curr Oncol 2021;28:2029-39. [PMID: 34073289 DOI: 10.3390/curroncol28030188] [Reference Citation Analysis]
26 Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood 2019;133:81-93. [PMID: 30446494 DOI: 10.1182/blood-2018-07-865428] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
27 Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. J Hematol Oncol 2019;12:65. [PMID: 31242924 DOI: 10.1186/s13045-019-0750-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zhou X, Dierks A, Kertels O, Kircher M, Schirbel A, Samnick S, Buck AK, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Kortüm KM, Rasche L, Einsele H, Lapa C. 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers (Basel) 2020;12:E2333. [PMID: 32824832 DOI: 10.3390/cancers12082333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122:4172-81. [PMID: 24144641 DOI: 10.1182/blood-2013-08-520890] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
30 Yang C, Cimera RS, Aryeequaye R, Jayakumaran G, Sarungbam J, Al-Ahmadie HA, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Epstein JI, Reuter VE, Zhang Y, Chen YB. Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Mod Pathol 2021;34:445-56. [PMID: 32879414 DOI: 10.1038/s41379-020-00667-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Li C, Wendlandt EB, Darbro B, Xu H, Thomas GS, Tricot G, Chen F, Shaughnessy JD Jr, Zhan F. Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. Cancers (Basel) 2021;13:517. [PMID: 33572851 DOI: 10.3390/cancers13030517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021;10:336. [PMID: 33562668 DOI: 10.3390/cells10020336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Brandelik SC, Krzykalla J, Hielscher T, Hillengass J, Kloth JK, Kauczor HU, Weber MA. [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis]. Radiologe 2018;58:72-8. [PMID: 28905085 DOI: 10.1007/s00117-017-0299-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Lionetti M, Da Vià MC, Albano F, Neri A, Bolli N, Musto P. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? Cancers (Basel) 2021;13:3319. [PMID: 34282760 DOI: 10.3390/cancers13133319] [Reference Citation Analysis]
35 Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression. Oncotarget 2015;6:39165-83. [PMID: 26472281 DOI: 10.18632/oncotarget.5381] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
36 Cypris O, Božić T, Wagner W. Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? Front Genet 2019;10:785. [PMID: 31552094 DOI: 10.3389/fgene.2019.00785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv 2018;2:2607-18. [PMID: 30327369 DOI: 10.1182/bloodadvances.2018023200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
38 . Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol 2018;93:981-1114. [PMID: 30400719 DOI: 10.1002/ajh.25117] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 27.7] [Reference Citation Analysis]
39 Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K, Gentile TC. Recent Advances in the Management of Smoldering Multiple Myeloma. World J Oncol 2020;11:45-54. [PMID: 32284772 DOI: 10.14740/wjon1245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:719-34. [PMID: 27291302 DOI: 10.1002/ajh.24402] [Cited by in Crossref: 241] [Cited by in F6Publishing: 228] [Article Influence: 60.3] [Reference Citation Analysis]
41 Sundararajan S, Kumar A, Korde N, Agarwal A. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Curr Hematol Malig Rep 2016;11:102-10. [PMID: 26894382 DOI: 10.1007/s11899-016-0305-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
42 Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica 2017;102:1432-8. [PMID: 28495913 DOI: 10.3324/haematol.2017.168005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
43 Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol 2020;33:101152. [PMID: 32139017 DOI: 10.1016/j.beha.2020.101152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget 2015;6:3319-34. [PMID: 25669970 DOI: 10.18632/oncotarget.3207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
45 Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest 2015;125:2077-89. [PMID: 25893601 DOI: 10.1172/JCI77181] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
46 Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-606. [PMID: 27737890 DOI: 10.1182/blood-2016-09-692954] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
47 Tomasson MH, Ali M, De Oliveira V, Xiao Q, Jethava Y, Zhan F, Fitzsimmons AM, Bates ML. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int J Mol Sci 2018;19:E3621. [PMID: 30453544 DOI: 10.3390/ijms19113621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
48 Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59. [PMID: 29895887 DOI: 10.1038/s41408-018-0077-4] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 28.3] [Reference Citation Analysis]
49 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
50 Mateos MV, Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat Res 2016;169:3-12. [PMID: 27696254 DOI: 10.1007/978-3-319-40320-5_1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
51 Zhao JT, Jiang XY, Yang C, Chen M, Lan XL, Du JH, Zhou DB, Zhuang JL. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10]. Zhonghua Xue Ye Xue Za Zhi 2021;42:295-301. [PMID: 33979973 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.005] [Reference Citation Analysis]
52 Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J 2019;9:32. [PMID: 30846679 DOI: 10.1038/s41408-019-0191-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
53 Landgren O. Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program 2017;2017:194-204. [PMID: 29222256 DOI: 10.1182/asheducation-2017.1.194] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
54 Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, Yang L, Wang J, Tang H, Xie X. circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression. Theranostics 2018;8:4003-15. [PMID: 30083277 DOI: 10.7150/thno.24106] [Cited by in Crossref: 101] [Cited by in F6Publishing: 118] [Article Influence: 33.7] [Reference Citation Analysis]
55 López-Corral L, Corchete LA, Sarasquete ME, Mateos MV, García-Sanz R, Fermiñán E, Lahuerta JJ, Bladé J, Oriol A, Teruel AI, Martino ML, Hernández J, Hernández-Rivas JM, Burguillo FJ, San Miguel JF, Gutiérrez NC. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica 2014;99:1365-72. [PMID: 24816239 DOI: 10.3324/haematol.2013.087809] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
56 Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep 2020;12:8951. [PMID: 33042502 DOI: 10.4081/hr.2020.8951] [Reference Citation Analysis]
57 Bhutani M, Landgren O. [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future]. Radiologe 2014;54:572, 574-81. [PMID: 24927659 DOI: 10.1007/s00117-014-2694-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
58 Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268. [PMID: 28814763 DOI: 10.1038/s41467-017-00296-y] [Cited by in Crossref: 142] [Cited by in F6Publishing: 134] [Article Influence: 35.5] [Reference Citation Analysis]
59 Mateos MV, González-Calle V. Timing of treatment of smoldering myeloma: early treatment. Blood Adv 2018;2:3045-9. [PMID: 30425068 DOI: 10.1182/bloodadvances.2018021220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
60 Moser-Katz T, Joseph NS, Dhodapkar MV, Lee KP, Boise LH. Game of Bones: How Myeloma Manipulates Its Microenvironment. Front Oncol 2020;10:625199. [PMID: 33634031 DOI: 10.3389/fonc.2020.625199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015;125:3069-75. [PMID: 25838344 DOI: 10.1182/blood-2014-09-568899] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 22.5] [Reference Citation Analysis]
62 Luo SQ, Xiong DH, Li J, Li G, Wang Y, Zhang JM, Bu XF, Hu WX, Hu J. C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. Oncogene 2020;39:3354-66. [PMID: 32103167 DOI: 10.1038/s41388-020-1222-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
63 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers (Basel) 2020;12:E2537. [PMID: 32906608 DOI: 10.3390/cancers12092537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 2014;123:2504-12. [PMID: 24497533 DOI: 10.1182/blood-2013-12-546077] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
65 Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454. [PMID: 27471870 DOI: 10.1038/bcj.2016.65] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
66 Hanamura I. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. Cancers (Basel) 2021;13:E256. [PMID: 33445467 DOI: 10.3390/cancers13020256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res 2016;5:F1000 Faculty Rev-2053. [PMID: 27610224 DOI: 10.12688/f1000research.8777.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
68 Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018;3:98259. [PMID: 29669929 DOI: 10.1172/jci.insight.98259] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
69 Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell 2017;32:88-100.e6. [PMID: 28669490 DOI: 10.1016/j.ccell.2017.05.011] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 13.0] [Reference Citation Analysis]
70 Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 2015;5:e365. [PMID: 26517360 DOI: 10.1038/bcj.2015.92] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
71 Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017;17:543-56. [PMID: 28835722 DOI: 10.1038/nrc.2017.63] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
72 Ahn IE, Mailankody S, Korde N, Landgren O. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol 2015;33:115-23. [PMID: 25422486 DOI: 10.1200/JCO.2014.56.4351] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
73 Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 2021;11:83. [PMID: 33927196 DOI: 10.1038/s41408-021-00474-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Salem KZ, Ghobrial IM. The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs 2015;3. [PMID: 25995973 DOI: 10.1517/21678707.2015.1036740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
75 Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 2017;102:1617-25. [PMID: 28550183 DOI: 10.3324/haematol.2017.163766] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
76 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
77 Meißner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC Med Genomics 2015;8:85. [PMID: 26714877 DOI: 10.1186/s12920-015-0161-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]